BackNewAmsterdam Pharma Company NV Overview

NewAmsterdam Pharma Company NV Total Revenue

Revenue analysis for NAMS.

Quarterly Revenue

$3.04M
↑ 2.08% YoY

As of Mar 2026

Annual Revenue (TTM)

$22.57M
↓ 52.13% YoY

Trailing 12 months ending Mar 2026

Average Revenue (Comparison Companies)

Loading

Total Revenue History

Loading

Total Revenue Comparison

Loading

Annual Revenue Growth Rate (%)

Loading

Annual Revenue Growth (Absolute)

Loading
Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin